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MembraneHost defense peptides are key components of the innate immune system, providing multi-facetted responses to
invading pathogens. Here, we describe that the peptide GKS26 (GKSRIQRLNILNAKFAFNLYRVLKDQ), correspond-
ing to the A domain of heparin cofactor II (HCII), ameliorates experimental septic shock. The peptide displays an-
timicrobial effects through direct membrane disruption, also at physiological salt concentration and in the
presence of plasma and serum. Biophysical investigations of model lipid membranes showed the antimicrobial
action of GKS26 to be mirrored by peptide incorporation into, and disordering of, bacterial lipid membranes.
GKS26 furthermore binds extensively to bacterial lipopolysaccharide (LPS), as well as its endotoxic lipid A moi-
ety, and displays potent anti-inﬂammatory effects, both in vitro and in vivo. Thus, for mice challenged with ip in-
jection of LPS, GKS26 suppresses pro-inﬂammatory cytokines, reduces vascular leakage and inﬁltration in lung
tissue, and normalizes coagulation. Together, these ﬁndings suggest that GKS26may be of interest for further in-
vestigations as therapeutic against severe infections and septic shock.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Antimicrobial and host defense peptides play a central role in
the protection against invading pathogens, providing antimicrobial,
anti-inﬂammatory, as well as other effects [1,2]. With increasing
resistance development against conventional antibiotics, as well as
remaining challenges in the treatment of both acute and chronic inﬂam-
mation, such peptides have been the subject of considerable research
interest during the last decade. As part of this, various approaches
have been employed for identiﬁcation of potent, but simultaneously
selective, peptides, including, e.g., quantitative structure-activity
approaches [3]. Within context, we have focused our efforts primarily
on peptides derived from endogenous proteins, including complement,
coagulation, andmatrix proteins, displayingpotent antimicrobial effects
but also low toxicity to human cells. In addition to such directly anti-
microbial effects, some of these studies have also been demonstrated
to display potent anti-inﬂammatory capacity, able to counteract the
multiple detrimental effects of bacterial lipopolysaccharide (LPS) from
Gram-negative bacteria, as well as related effects from lipoteichoic
acid (LTA) from Gram-positive bacteria and zymosan from fungi [4,5].
In our work with coagulation-based host defense peptides and
holoproteins, we previously investigated the serine proteinase inhibitor6 184714377.
almsten).
ights reserved.heparin cofactor II (HCII), and were able to demonstrate a novel host
defense function of this protein [6]. Thus, compared to normal mice,
HCII−/− knock-outs were found to be more susceptible to LPS-induced
shock and invasive infection by Pseudomonas aeruginosa. Concomitant-
ly, a signiﬁcantly increased cytokine response was observed in HCII−/−
mice in response to infection, and HCII levels were reduced in infected
normal mice. The LPS-binding, as well as antimicrobial capacity, of acti-
vated HCIIwas furthermore found to be dependent on a conformational
change, exposing the amphiphilic and positively charged A and D heli-
ces of HCII.
Having shown that these helices are important for the host defense
function of HCII, we hypothesized that the epitopes alone could
potentially maintain some functional properties of the holoprotein,
thus offering interesting opportunities as simpler therapeutic agents.
We here describe biological activities of a helix A-derived peptide of
HCII, GKS26 (GKSRIQRLNILNAKFAFNLYRVLKDQ), spanning the entire
length of the helix. In doing so, we report on its antimicrobial and
anti-inﬂammatory properties, using a battery of assays for broad effect
characterization. In parallel, biophysical investigations provided
additional insight into the mechanisms underlying these effects. The
peptide exerted potent antibacterial and anti-inﬂammatory activities,
and showed efﬁciency in a model of endotoxin-induced shock in vivo.
Taken together, the results thus demonstrate this peptide to be of
potential interest in the development of novel anti-infective and anti-
inﬂammatory therapies.
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2.1. Chemicals
GKS26 (Table 1) was synthesized by Biopeptide Co., San Diego, USA,
andwas of N95% purity, as evidenced bymass spectral analysis (MALDI-
TOF Voyager). LPS and lipid A from Escherichia coli (0111:B4 and F583
(Rd mutant), respectively) were from Sigma (St. Louis, USA). In LPS
(N500,000 EU/mg), protein and RNA content were both less than 1%.2.2. Microorganisms
E. coli ATCC 25922, P. aeruginosa ATCC 27853, Staphylococcus aureus
(S. aureus) ATCC 29213, and Bacillus subtilis (B. subtilis) ATCC 6633
isolates were obtained from the Department of Clinical Bacteriology at
Lund University Hospital, Sweden.2.3. Scanning electron microscopy
Bacteria were grown in TH medium at 37 °C to mid-logarithmic
phase. The bacteria were washed in buffer (10 mM Tris, pH 7.4, 0.15
M NaCl, 5 mM glucose) and resuspended in the same buffer. Peptides
at 30 μM were incubated with S. aureus ATCC 29213 or P. aeruginosa
ATCC 27853 (1 × 108 bacteria) for 2 h in a total volume of 50 ml in
10 mM Tris, pH 7.4, with additional 150 mM NaCl. Bacteria were ﬁxed
and prepared for scanning electron microscopy as described previously
[7]. Samples were examined with a Philips/FEI CM 100 electron micro-
scope operated at 80 kV accelerating voltage and images recorded
with a side-mounted Olympus Veleta camera at the Core Facility for
integrated Microscopy (CFIM), Copenhagen University, Denmark.2.4. Fluorescence microscopy
Formonitoring ofmembrane permeabilization using the impermeant
probe FITC (Sigma-Aldrich, St. Louis, USA), E. coli ATCC 25922 bacteria
were grown to mid-logarithmic phase in TSB medium. Bacteria were
washed and re-suspended in buffer (10 mM Tris, pH 7.4, 0.15 M NaCl)
to yield a suspension of 1 × 107 CFU/ml. 100 ml of the bacterial
suspension was incubated with 30 μM of the respective peptides
at 37 °C for 60 min. Microorganisms were then immobilized on poly
(L-lysine)-coated glass slides by incubation for 45min at 30 °C, followed
by addition onto the slides of 200 ml of FITC (6 mg/ml) in buffer and
incubation for 30 min at 30 °C. The slides were washed and bacteria
ﬁxed by incubation, ﬁrst on ice for 15 min, then in room temperature
for 45 min in 4% paraformaldehyde. The glass slides were subsequently
mounted on slides using Prolong Gold anti-fade reagent mounting
medium (Invitrogen, Eugene, USA). For ﬂuorescence analysis, bacteria
were visualized using a Nikon Eclipse TE300 (Nikon, Melville, USA)
inverted ﬂuorescence microscope equipped with a Hamamatsu
C4742-95 cooled CCD camera (Hamamatsu, Bridgewater, USA) and
a Plan Apochromat ×100 objective (Olympus, Orangeburg, USA).
Differential interference contrast (Nomarski) imaging was used for
visualization of the microbes themselves.Table 1
Sequence and key properties of GKS26.
Sequence IP1 Znet2 (pH 7.4) H3
GKS26 GKSRIQRLNILNAKFAFNLYRVLKDQ 11.49 +5 −0.42
1 IP: isoelectric point.
2 Znet: net charge.
3 H means hydrophobicity on the Kyte-Doolittle scale [41].2.5. Liposome preparation and leakage assay
Model liposomes investigated were anionic (DOPE/DOPG
75/25 mol/mol), frequently used as bacteria membrane models [8].
DOPG (1,2-dioleoyl-sn-Glycero-3-phosphoglycerol, monosodium salt)
and DOPE (1,2-dioleoyl-sn-Glycero-3-phosphoethanolamine) were
from Avanti Polar Lipids (Alabaster, USA) and of N99% purity. In addi-
tion, reconstituted lipid membranes were used based on polar extract
of E. coli, with a lipid composition of 67.0% phosphatidylethanolamine,
23.2% phosphatidylglycerol, and 9.8% diphosphatidylglycerol (Avanti
Polar Lipids; Alabaster, USA). The lipid mixture was dissolved in
chloroform, after which solvent was removed by evaporation under
vacuum overnight. Subsequently, 10 mM Tris buffer, pH 7.4, was
added together with 0.1 M carboxyﬂuorescein (CF) (Sigma, St. Louis,
USA). After hydration, the lipid mixture was subjected to eight freeze–
thaw cycles (not for E. coli liposomes), consisting of freezing in liquid
nitrogen and heating to 60 °C. Unilamellar liposomes of about
Ø140 nmwere generated bymultiple extrusions (30 passages) through
polycarbonate ﬁlters (pore size 100 nm) mounted in a LipoFast
miniextruder (Avestin, Ottawa, Canada) at 22 °C. Untrapped CF was
removed by two subsequent gel ﬁltrations (Sephadex G-50, GE
Healthcare, Uppsala, Sweden) at 22 °C, with Tris buffer as eluent. CF
release from the liposomes was determined by monitoring the emitted
ﬂuorescence at 520 nm from a liposome dispersion (10 μM lipid in
10 mM Tris, pH 7.4). For the leakage experiment in the presence of
LPS, 0.02 mg/ml LPS was ﬁrst added to the above liposome dispersion
(which did not cause liposome leakage in itself; results not shown),
after which peptide was added and leakage monitored as a function
of time. An absolute leakage scale was obtained by disrupting the
liposomes at the end of each experiment through addition of 0.8 mM
Triton X-100 (Sigma-Aldrich, St. Louis, USA). A SPEX-ﬂuorolog 1650
0.22-m double spectrometer (SPEX Industries, Edison, USA) was used
for the liposome leakage assay. Measurements were performed in
triplicate at 37 °C.
2.6. CD spectroscopy
Circular dichroism (CD) spectra were measured by a Jasco J-810
Spectropolarimeter (Jasco, Easton, USA). Measurements were
performed in duplicate at 37 °C in a 10 mm quartz cuvette under stir-
ring with a peptide concentration of 10 μM. The effect on peptide sec-
ondary structure of liposomes at a lipid concentration of 100 μM was
monitored in the range 200–260 nm. The α-helix content was calculat-
ed from the recorded CD signal at 225 nm using reference peptides in
purely helical and random coil conformations, respectively. 100% α-
helix and 100% random coil references were obtained from 0.133 mM
(monomer concentration) poly-L-lysine (Mw = 79 kDa) in 0.1 M
NaOH and 0.1 M HCl, respectively. For measurements in the presence
of LPS, 0.2 mg/ml was used. To account for instrumental differences be-
tween measurements, background subtraction was performed routine-
ly. Signals from the bulk solution were also corrected.
2.7. Ellipsometry
Peptide adsorption to supported lipid bilayers was studied in situ by
null ellipsometry, using an Optrel Multiskop (Optrel, Kleinmachnow,
Germany) equipped with a 100 mW Nd:YAG laser (JDS Uniphase,
Milpitas, USA). All measurements were carried out at 532 nm and
an angle of incidence of 67.66° in a 5 ml cuvette under stirring
(300 rpm). Both the principles of null ellipsometry and the procedures
used have been described extensively before [9]. In brief,measurements
were ﬁrst made on the bare silica surface, which allows its complex
refractive index to be determined. These parameters were subsequently
used together with new sets of the optical component positions after
adsorbed layer formation for determining the thickness and refractive
index of the adsorbed layer. From this, the mean refractive index (n)
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thickness and refractive index the adsorbed amount (Γ) was calculated
according to:
Γ¼ n−n0ð Þ
dn=dc
d ð1Þ
where n0 is the refractive index of the bulk solution, and dn/dc the
refractive index increment (0.154 cm3/g). Corrections were routinely
done for changes in bulk refractive index caused by changes in temper-
ature and excess electrolyte concentration.
LPS-coated surfaces were obtained by adsorbing E. coli LPS to
methylated silica surfaces (surface potential −40 mV, contact angle
90° [10]) from 5 mg/ml LPS stock solution in water at a concentration
of 0.4 mg/ml over a period of 2 h. This results in a hydrophobically
driven LPS adsorption of 1.48 ± 0.38 mg/m2, corresponding to plateau
in the LPS adsorption isotherm under these conditions. Non-adsorbed
LPS was removed by rinsing with Tris buffer at 5 ml/min for a period
of 30 min, followed by buffer stabilization for 20 min. Peptide addition
was performed at different concentrations of 0.01, 0.1, 0.5, and 1 μM,
and the adsorption monitored for 1 h after each addition. All measure-
ments were performed in at least duplicate at 25 °C. For lipid A deposi-
tion, this was solubilized with 0.25 wt.% triethyl amine (TEA) under
vigorous vortexing and heating to 60 °C for 10 min. Lipid A was
adsorbed at methylated silica surfaces for 2 h from 5 mg/ml lipid A
stock solution in 0.25% TEA at a concentration of 0.4 mg/ml in 10 mM
Tris, pH 7.4, containing 150 mM NaCl. Non-adsorbed lipid A was
subsequently removed by rinsing with the same buffer at 5 ml/min
for 15 min, followed by buffer stabilization for 20 min. This results in a
lipid A adsorption of 0.8 ± 0.2 mg/m2. Peptide addition was subse-
quently performed to 0.01, 0.1, 0.5, and 1 μM, and adsorptionmonitored
for 1 h after each addition. All measurements were performed in at least
duplicate at 25 °C.
Supported lipid bilayers were generated by liposome adsorption.
DOPE/DOPG (75/25 mol/mol) liposomes were prepared as described
above, but the dried lipid ﬁlms resuspended in Tris buffer only with
no CF present. In order to avoid adsorption of peptide directly at the
silica substrate through any defects of the supported lipid layer, poly-
L-lysine (Mw = 170 kDa, Sigma-Aldrich, St. Louis, USA) was
preadsorbed from water prior to lipid addition to an amount of 0.045
± 0.01 mg/m2, followed by removal of nonadsorbed poly-L-lysine by
rinsing with water at 5 ml/min for 20 min [11]. Water in the cuvette
was then replaced by buffer containing also 150 mM NaCl, followed
by addition of liposomes in buffer at a lipid concentration of 20 μM,
and subsequently by rinsing with buffer (5 ml/min for 15 min) when
liposome adsorption had stabilized. The ﬁnal layer formed had structural
characteristics (thickness 4± 1 nm,mean refractive index 1.47± 0.03),
suggesting that a layer fairly close to a complete bilayer is formed.
After lipid bilayer formation, the cuvette content was replaced by
10 mM Tris buffer at a rate of 5 ml/min over a period of 30 min.
After stabilization for 40 min, peptide was added to a concentration
of 0.01 μM, followed by three subsequent peptide additions to
0.1 μM, 0.5 μM, and 1 μM, in all cases monitoring the adsorption for
1 h. All measurements were made in at least duplicate at 25 °C.
2.8. Dual polarization interferometry
Peptide disordering of DOPE/DOPG supported bilayers were investi-
gated by dual polarization interferometry (DPI), using a Farﬁeld
AnaLight 4D (Biolin Farﬁeld, Manchester, U.K.), operating with an alter-
nating 632.8 nm laser beam. The technique is based on a dual slab
waveguide, consisting of an upper sensing waveguide (supporting the
lipid bilayer) and a lower reference waveguide. The changes induced
by the peptide/lipid adsorption were monitored through changes in
the transverse electric and transverse magnetic modes as described
previously [12]. As for ellipsometry, Eq. (1) was used for determiningthe mass adsorbed. Although treating phospholipids as optically
isotropic systems is a reasonably accurate approximation for unsaturat-
ed and disorganized phospholipid bilayers, these actually display some
optical birefringence, which is measurable with the sensitive DPI tech-
nique. DPI allows two parameters to be obtained from each
measurement, e.g., for the simultaneous determination of two optical
parameters of the adsorbed layer. The latter were chosen to be the
adsorbed amount and the anisotropy, assuming the adsorbed layer
thickness to be constant during the adsorption process. The birefrin-
gence (Δnf), obtained from the refractive indices for the TM and TE
waveguidemodes, reﬂects ordering of the lipidmolecules in the bilayer,
and decreases with increasing disordering of the bilayer [13]. Conse-
quently, Δnf can be used to monitor disordering transitions in lipid
bilayers, e.g., as a result of peptide binding and incorporation, and
therefore offers a simpler alternative to, e.g., order parameter analyses
in 2H NMR spectroscopy [14]. In the present study, DOPE/DOPG
liposomes (75/25 mol/mol) were prepared as described above for
ellipsometry, and the liposomes (at a lipid concentration of 0.2 mg/ml
in 10 mM HEPES buffer, containing also 150 mM NaCl and 1.5 mM
CaCl2) fused to the silicon oxynitride/silicon substrate (contact angle
b5°) at a ﬂow rate of 25 μl/min for 8 min. This resulted in bilayer
formation, characterized by a refractive index of 1.47, a thickness of
4.5± 0.3 nm, and an area permolecule of 54 Å2. After bilayer formation,
the buffer was changed to 10 mM Tris buffer, allowing continuous
ﬂushing (at ﬂow rate, 50 μl/min) for 10 min, after which peptide was
added at the desired concentration. Peptide adsorption was monitored
for 1 h. Measurements were performed at least in duplicate at 25 °C.
2.9. Radial diffusion assay
Essentially as described before [15,16], bacteria were grown to mid-
logarithmic phase in 10ml of full-strength (3%w/v) trypticase soy broth
(TSB) (Becton-Dickinson, Cockeysville, USA) (enzymatic digest of
casein (17 g/l) and soybean (3 g/l), glucose (2.5 g/l), sodium chloride
(5 g/l), and dipotassium hydrogen phosphate (2.5 g/l), pH 7.3). The
microorganisms were then washed once with 10 mM Tris, pH 7.4.
Subsequently, 4 × 106 bacterial colony forming units (cfu) were added
to 15 ml of the underlay agarose gel, consisting of 0.03% (w/v) TSB, 1%
(w/v) low electroendosmosis type (EEO) agarose (Sigma-Aldrich, St
Louis, USA), and 0.02% (v/v) Tween 20 (Sigma-Aldrich, St Louis, USA),
with or without 150 mM NaCl. The underlay was poured into a Ø
144 mm Petri dish. After agarose solidiﬁcation, 4 mm-diameter wells
were punched and 6 μl of test sample added to eachwell. Plateswere in-
cubated at 37 °C for 3 h to allow diffusion of the peptides. The underlay
gel was then coveredwith 15ml ofmolten overlay (6% TSB and 1% Low-
EEO agarose in distilled H2O). Antimicrobial activity of a peptide is visu-
alized as a zone of clearing around eachwell after 18–24 h of incubation
at 37 °C.
2.10. Viable-count analysis
Bacteria were grown tomid-logarithmic phase in Todd–Hewitt (TH)
medium (heart infusion (3.1 g/l), yeast-enriched peptone (20 g/l),
glucose (2 g/l), sodium chloride (2 g/l), disodium phosphate (0.4 g/l),
and sodium carbonate (2.5 g/l), pH 7.8), and then washed and diluted
in 10 mM Tris, pH 7.4, 5 mM glucose, and 0.15 M NaCl. Following this,
bacteria (50 μl of 2 × 106 cfu/ml) were incubated at 37 °C for 2 h in
the presence of peptide at indicated concentrations in 10 mM Tris,
0.15 M NaCl, with or without 20% human citrate-plasma (CP) or 20%
serum. Serial dilutions of the incubation mixture were plated on TH
agar, followed by incubation at 37 °C overnight and cfu determination.
2.11. LPS effects on macrophages in vitro
RAW 276.4 cells (3.5 × 106 cells/ml) (ATCC TIB 71, American Type
Culture Collection, Manassas, USA) were seeded in 96-well tissue
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medium (DMEM; PAA laboratories) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (FBS; Invitrogen) and 1% (v/v)
Antibiotic–Antimycotic solution (ASS; Invitrogen). After 20 h of incuba-
tion to permit adherence, cellswere stimulatedwith 10 ng/ml E. coli LPS
(0111:B4) (Sigma-Aldrich), and various doses of GKS26. The level of
nitrite oxide (NO) in culture supernatants was determined after 20 h
incubation at 37 °C and 5% CO2 using the Griess reaction as described
previously [17]. In addition, RAW-Blue™ cells (1 × 106 cells/ml)
(InvivoGen) were seeded in phenol red-free DMEM, supplemented
with 10% (v/v) heat-inactivated FBS and 1% (v/v) AAS, and allowed to
adhere before they were stimulated with 10–1000 ng/ml E. coli (0111:
B4) LPS and 10 μM GKS26. NF-κB activation was determined after 20 h
of incubation according to themanufacturer's instructions (InvivoGen).
Brieﬂy, activation of NF-κB leads to the secretion of embryonic alkaline
phosphatase (SEAP) into the cell supernatant were it was measured by
mixing supernatants with a SEAP detection reagent (Quanti-Blue™,
InvivoGen) followed by measurement of the absorbance (A) at 600 nm.
2.12. Lactate dehydrogenase assay
RAW-Blue™ cells (5–6 × 106 cells/ml) were stimulated as described
for the NF-κB activation assay. Lactate dehydrogenase (LDH) release
was quantiﬁed using the TOX-7 kit (Sigma-Aldrich). After incubation
overnight, 50 μl of cell supernatant was mixed with 100 μl LDH reagent
mixture, incubated for 5–10min at RT in the dark before absorptionwas
measured at 490 nm. The percentage of LDH release was calculated as
follows: ((A490 sample− A490 negative control) ∗ 100) / (A490 positive
control − A490 negative control). The positive control consistent of
cells lysed with LDH lysis buffer for 45 min, at 37 °C considered as
100% LDH release.
2.13. Whole blood assay
Human lepirudin blood from healthy volunteers was diluted in PBS
(1:4 v/v) before the addition of 100 ng/ml E. coli (0111:B4) LPS and
10 μMGKS26. After incubation at 37 °C overnight, 5% CO2 in cell culture
plates (Nunc), samples were centrifuged and supernatants were
collected and stored at−20 °C prior to cytokine analysis.
2.14. LPS animal model
All animal experiments were approved by the Laboratory Animal
Ethics Committee of Malmö/Lund, Sweden. The animals were obtained
from the animal facility at the University of Lund, and housed under
standard conditions of light and temperature with free access to labora-
tory chowandwater.Male C57BL/6mice (8 weeks)were injected intra-
peritoneally (ip) with 18 mg/kg E. coli 0111:B4 LPS (Sigma-Aldrich,
≈500.000 endotoxin units/mg). Thirty minutes after LPS injection,
200 or 500 μg GKS26 in 10 mM Tris, pH 7.4, or buffer alone (control),
was injected ip into the mice. The mice were sacriﬁced after 20 h to
determine platelet counts, cytokines, and coagulation parameter. The
number of platelets was determined using the VetScan HM5 System
(TRIOLAB, Mölndal, Sweden).
2.15. Histochemistry
Organswere collected 20 h after LPS injection and immediately ﬁxed
in 4% formaldehyde (Histolab AB, Göteborg, Sweden) prior to parafﬁn
embedding and sectioning. Sections were stained with Mayers
Haematoxylin (Histolab AB, Göteborg, Sweden) and Eosin (Merck).
2.16. Cytokine assay
The levels of IL-6, IL-10, MCP-1, INF-γ, and TNF-α were assessed
using the Mouse Inﬂammation Kit (Becton Dickinson AB, Stockholm,Sweden), according to the manufacturer's instructions. The levels
of IL-6, TNF-α, and IL-10 were measured in supernatants of whole
blood using CytoSets™ (Invitrogen) according to the manufacturer's
instructions.
2.17. Coagulation assays
Clotting times were analyzed using an Amelung coagulometer
(Lemgo, Germany). Activated partial thromboplastin time (aPTT) was
measured by incubating 50 μl citratedmouse plasma for 1min followed
by the addition of 50 μl Dapttin (Technoclone, Vienna Austria) for 200 s
at 37 °C. Clottingwas initiated by the addition of 50 μl of CaCl2 (30mM).
For the prothrombin time (PT), clottingwas initiated by addition of 50 μl
TriniClot-PT Excel (Trinity Biotech, Wicklow, Ireland) to 50 μl of pre-
warmed mouse citrate plasma.
3. Results
3.1. GKS26 is antimicrobial in vitro and ex vivo
First, radial diffusion (RDA) and viable count (VCA) assays were
performed to probe direct bactericidal effects of GKS26. As shown in
Fig. 1A and B, GKS26 displays potent antimicrobial effects against
Gram-negative E. coli and P. aeruginosa, as well as Gram-positive
S. aureus and B. subtilis. Furthermore, Fig. 1C demonstrates the similar
kinetics of this effect for E. coli and P. aeruginosa. While some of the an-
timicrobial activity is lost in the presence of serum, high antimicrobial
activity is observed in the presence of CP (Fig. 1B). The latter is notewor-
thy, since binding of cationic AMPs to net negatively charged serum
proteins frequently results in considerable loss in antimicrobial effects
[8]. The ﬁnding that plasma even accentuates the antimicrobial effects
demonstrates that ﬁbrinogen and other coagulation factors may in fact
contribute to bactericidal effects, presumably through membrane
interactions of highly surface active ﬁbrinogen [18,19]. Adding to this,
Fig. 2 shows GKS26 to display pronounced selectivity between bacteria
andmammalian cells. Thus, for P. aeruginosa and E. coli added to human
blood, the peptide is able to potently kill bacteria, but at the same time
does not cause hemolysis much above that of the negative control. For
S. aureus, this selectivity in blood is less pronounced.
3.2. GKS26 interacts with bacterial lipid membranes
As demonstrated by peptide-induced release of intracellular materi-
al, as well as by FITC permeation, the antimicrobial effect of GKS26 is
caused by bacterial membrane lysis (Fig. 3A and B). Analogously,
GKS26 causes lysis of liposomes composed of model anionic phospho-
lipids (DOPE/DOPG), as well as liposomes composed of E. coli lipid
extract (Fig. 4). As seen, the DOPE/DOPG model liposomes behaved
similarly to liposomes formed by E. coli lipid extract, demonstrating
the experimentally preferred DOPE/DOPG to be a good model for
E. coli lipid membranes. Taken together, the combined bacteria and
liposome data clearly show bacterial membrane disruption to play a
key role in the antimicrobial action of GKS26.
Themechanism of lipidmembrane disruptionwas next investigated
by studies of peptide binding, insertion, and disordering to/of supported
lipid membranes. As shown in Fig. 5A, GKS26 displays concentration-
dependent adsorption at the anionic DOPE/DOPG lipid membrane,
reaching high adsorption densities at concentration corresponding
to maximum membrane lysis. Thus, an adsorption density of
≈450 nmol/m2 corresponds to one peptide molecule per 8 lipid mole-
cules. As shown in Fig. 5B, peptide binding to supported DOPE/DOPG
lipid bilayers results in amonotonous decrease in themembrane optical
anisotropy, indicating that peptide adsorption results in disordering of
the lipid membrane. Importantly, there is no threshold for membrane
insertion. Instead, the DPI results clearly report on a continuous process,
where all peptides bound to the membrane are inserted into the
Fig. 1.Antimicrobial activity. (A) Antimicrobial activity of GKS26 (at 100 μM), as obtained byRDA, against the indicatedmicrobes. Bacteria (4×106 cfu)were inoculated in 0.1% TSB agarose
gel, followedby peptide addition to 4mm-diameterwells. Clearance zones correspond to the inhibitory effect of each peptide after incubation at 37 °C for 18–24 h. (B) Antibacterial effects
of GKS26 against the indicated bacterial strains in viable count assays. 2 × 106 cfu/ml bacteria were incubated in 50 μl with peptides at the indicated concentrations in 10 mM Tris, con-
taining 0.15 M NaCl (buffer), in 10 mM Tris, 0.15 M NaCl, pH 7.4, containing 20% human citrate plasma (CP), or in 20% human serum (Serum). (C) Kinetics of GKS26 killing of E. coli and
P. aeruginosa at a peptide concentration of 3 μM in 10 mM Tris, 0.15 M NaCl, pH 7.4. (n = 3).
Fig. 2.GKS26 toxicity vs. antimicrobial activity inhumanwholeblood. The indicated bacteria (2× 108 cfu/ml)were incubated in 50%human citrate bloodwith orwithout 60 and 120 μMof
peptide, followed by determination of cfu by VCA (A) and hemolysis (B). (n = 3).
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Fig. 3. Permeabilizing effects of GKS26 on bacteria. (A) E. coliwas incubated with 30 μM
peptide in 10 mM Tris, pH 7.4, and permeabilization was assessed using the impermeant
probe FITC. (B) Scanning electron microscopy images of P. aeruginosa and S. aureus before
and after incubation with 30 μM peptide for 2 h at 37 °C.
Fig. 5. Peptide adsorption. (A) Peptide binding to supportedDOPE/DOPG (75/25 mol/mol)
bilayers. (B) Peptide-induced membrane destabilization, monitored by DPI for DOPE/
DOPG supported bilayers (75/25 mol/mol). Measurements were performed in 10 mM
Tris, pH 7.4, and data reported as reduction in Δnf, the lipid membrane birefringence,
1230 P. Papareddy et al. / Biochimica et Biophysica Acta 1838 (2014) 1225–1234membrane (as opposed to sitting on-top), throughout the binding pro-
cess, undergoing modest conformational changes in the process
(Fig. 5C).Fig. 4. Liposome leakage induction. Peptide-induced liposome leakage for E. coli andDOPE/
DOPG (75/25 mol/mol) liposomes, as well as leakage from DOPE/DOPG liposomes in the
presence of 0.02 mg/ml E. coli LPS. Measurements were performed in 10 mM Tris,
pH 7.4. (n = 3).
(due to peptide insertion andmembrane disordering) as a function of the adsorption den-
sity of the peptide. (C) CD spectra in 10 mM Tris, pH 7.4, the absence and presence of
DOPE/DOPG liposomes (75/25 mol/mol; 100 μM lipid). (n = 3).3.3. GKS26 interacts with bacterial lipopolysaccharide and reduces LPS
responses in vitro, ex vivo, and in vivo
Moreover, GKS26 displays extensive binding to both E. coli LPS and
its endotoxic lipid A moiety (Fig. 6A), causing a pronounced structure
transition in the LPS/peptide complex (Fig. 6B). As shown in Fig. 4,
GKS26 binds preferentially to LPS over the lipid membrane. In previous
reports it has been shown that binding to LPS, especially the lipid A
moiety, is a prerequisite for anti-inﬂammatory effects of amphiphilic
peptides [20]. Therefore, experiments were performed to investigate
whether this is the case also for GKS26. Studies using mouse macro-
phages revealed that GKS26 dose-dependently reduced the LPS-
induced production of nitric oxide (Fig. 7A). After recognition of LPS
via the TLR4-MD2 complex, a signaling cascade is initiated leading to
the activation of NF-κB and ﬁnally to cytokine production and release
[21–23]. In experiments using a NF-κB reporter cell line (RAW Blue
Fig. 6. (A) Peptide binding to E. coli LPS and E. coli lipid A. (B) CD spectra for GKS26with or
without E. coli LPS (0.2 mg/ml). Shown also is the CD spectrum for LPS in the absence of
peptide. Measurements were performed in 10 mM Tris, pH 7.4. (n = 3).
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(Fig. 7B). Moreover the data reveal that this inhibition depends on theFig. 7. Effects of GKS26 on LPS-induced responses in vitro. (A) RAW264.7macrophages were st
Nitric oxide productionwasdetermined in the cell supernatants using theGriess reaction (n=3
LPS and 10 μMofGKS26. NF-κB activationwasmeasured after 20 h (n=5). (C) LDH release in s
treated blood was stimulated with 100 ng/ml E. coli LPS in combination with 10 μM GKS26. Indratio of LPS and peptide, indicating that direct LPS scavenging is indeed
important for this effect by GKS26. This is further supported by data
from a LDH assay, showing no toxic effects of the peptide on RAW-
Blue cells (Fig. 7C), thus the reduction is at least partly due to LPS–
GKS26 interactions and not due to toxicity. Moreover these LDH data
are consistent with reduced toxicity seen in blood (Fig. 2B). Finally, ef-
fects of GKS26 on LPS-induced cytokine release were determined
ex vivo using a whole blood model. The data show that GKS26 reduced
the pro-inﬂammatory cytokines TNF-α and IL-6, but had no effect on
anti-inﬂammatory IL-10 release (Fig. 7D).
Having demonstrated potential anti-inﬂammatory effects of GKS26
in vitro, but also ex vivo, a next set of experiments was performed to
investigate those in an in vivo context. C57BL/6 mice were challenged
with 18 mg/kg E. coli LPS and treated with either 200 μg of 500 μg of
GKS26. Consistent with the data of the whole blood experiments,
GKS26 treatment resulted in a dose-dependent reduction of the pro-
inﬂammatory cytokines IL-6, TNF-α, MCP-1, and IFN-γ, as well as in
IL-10 (Fig. 8A). In parallel, peptide treatment improved the overall
status of these animals as illustrated by improved health scoring (Fig.
8B).
Inﬂammation is an important initiator of coagulation [24]. Further-
more, systemic activation of coagulation is a compromising factor in
sepsis, characterized by consumption of coagulation factors and exces-
sive ﬁbrinolysis, leading to e.g. prolonged coagulation times and throm-
bocytopenia in patients [25]. Compatible to these symptoms are results
on platelet levels, as well as clotting times in mice challenged with LPS
(Fig. 8C and D). The latter displayed prolonged clotting times and a
signiﬁcant reduction in platelets, in contrast to mice treated with
GKS26, which showed normalization of both the activated partial
thromboplastin time (aPTT) and the prothrombin time (PT) (Fig. 8C),
as well less as partial recovery of platelet numbers (Fig. 8D). Examina-
tion of mouse lungs further revealed a reduction of disease symptoms,
as illustrated by reduced vascular leakage, inﬁltration of inﬂammatory
and red blood cells, and less reduction in alveolar space for peptide-
treated animals compared to LPS-treated ones (Fig. 8E), effects
particularly clear at the higher concentration of GKS26. Taken together,
these ﬁndings demonstrate that treatment with GKS26 dampenedimulatedwith 10 ng/ml E. coli LPS in combination with indicated concentrations of GKS26.
,mean± SEM). (B) RAWBlue cellswere stimulatedwith indicated concentrations of E. coli
upernatants of RAW-Blue cells from the experiments in (B) (n=3). (D)Human lepirudin-
icated cytokines were measured in plasma after 20 h of incubation (n = 5).
Fig. 8.Effects of GKS26 on LPS-induced responses in vivo. Septic shock inC57BL/6micewas induced by intraperitoneal (ip) injection of E. coli LPS (18 mg/kg) followedby ip injection of 200
or 500 μg of GKS26 or buffer. Effects were assessed 20 h post LPS-challenge. (A) Indicated cytokines were analyzed in plasma (LPS n = 12, GKS26200μg n = 5, GKS26500μg n = 11).
(B) Scoring ofmice status 20 h after LPS injection. (1; healthy, 4; septic shock (most severe scoring); Control n=6, LPS n=12, GKS26200μg n=6, GKS26500μg n=11). (C) Activated partial
thromboplastin time (aPTT) and prothrombin time (PT) were measured using citrate plasma (Control n = 6, LPS n = 10, GKS26200μg n = 5, GKS26500μg n = 11; Median indicated).
(D) Number of platelets was determined in mice 20 h after injection of LPS and treatment with GKS26 (Control n = 6, LPS n = 12, GKS26200μg n = 5, GKS26500μg n = 11). (E) Lungs
of non-treated (Control), LPS-challenged, and GKS26-treated mice were analyzed by histology. Representative light microscopy images stained with haematoxylin–eosin
(magniﬁcation 4×) are shown.
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inﬂammatory cytokines, vascular leakage, excessive coagulation, as well
as platelet consumption.
4. Discussion
With its high net charge and intermediate hydrophobicity (Table 1),
GKS26 is highly amphiphilic, thus binding readily to lipid membranes.
As demonstrated by the DPI experiments, peptide binding is accompa-
nied by peptide insertion into the membrane throughout the binding
process, without a threshold density prior to insertion. While the
interplay between peptide binding and insertion is relatively sparsely
investigated in literature, these ﬁndings are in line with results found
for aurein 1.2 on E. coli extract and DMPE/DMPG bilayers [26], HCII-
derived KYE28 [27], as well as peptides derived from S1 peptidases at
DOPE/DOPG bilayers [28]. As a result of peptide insertion into the lipid
membrane, the latter is destabilized, illustrated by peptide-induced
liposome leakage. Importantly, there is a clear correlation between
peptide binding density/insertion, destabilization of both model
DOPE/DOPG liposomes and liposomes composed of E. coli lipid extract,
and bacteria lysis, the latter in turn causing bactericidal effects. Impor-
tantly, however, GKS26 displays selectivity between bacteria and
human cells, demonstrated by the combined bactericidal and hemolysis
assays on blood supplemented with bacteria. Such selectivity has
previously been observed, e.g., for highly charged and simultaneouslymoderately hydrophobic peptides [29], and is due to lower peptide
binding caused by the lower charge density of the human cell
membranes, combined with resistance to peptide insertion caused by
the presence of cholesterol.
LPS is a negatively charged lipopolysaccharide, anchored to the outer
membrane in Gram-negative bacteria through its hydrophobic lipid A
moiety [20]. Through complex formation with lipopolysaccharide-
binding protein (LBP) by its lipid A moiety, and subsequent recognition
of CD14 and the Toll-like receptor 4 (TLR4), LPS causes an up-regulation
of pro-inﬂammatory cytokine production [21–23]. Consequently,
peptides can provide anti-endotoxic through direct binding to lipid A,
precluding or inhibiting LBP binding. It has also been found, however,
that LPS aggregates are particularly potent in their endotoxic effect
[30], presumably through providing an alternate cell uptake route to
the LBP/CD14 receptor one. Thus, peptides can reach anti-endotoxic ef-
fects also through causing disruption of LPS aggregates [27,31,32].
Mirroring this, it was recently demonstrated that peptide-induced LPS
disaggregation is correlated to pronounced structure transition in the
LPS/peptide complex [27,28], as presently observed for GKS26.
Due to its central role for the understanding of peptides of the innate
immune system, as well as the need for novel anti-inﬂammatory drugs,
the interaction between LPS and host defense peptides has been
previously investigated in literature. For example, Andrä et al. reported
on LPS interactions with the peptide NK-2, demonstrating both hydro-
phobic and electrostatic interactions to be necessary for efﬁcient LPS
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preference, Yang et al. found the rALF-Pm3 peptide to bind to a similar
extent to lipid A and LPS, but with a higher afﬁnity to lipid A [34].
Similarly, Brandenburg et al. demonstrated preferential binding of
lactoferrin to lipid A [35]. These ﬁndings are in line with the present
ﬁndings for GKS26, demonstrating a comparable adsorption density at
LPS and its lipid A moiety, despite considerably less binding sites
in the latter. Also addressing the issue of binding afﬁnity, Singh et al.
found that the binding of cationic peptides is stronger for LPS than for
the lipid membrane, and strongest for the lipid A moiety of LPS [27].
Thus, the presence of both membrane-bound and non-adsorbed LPS
will compete successfully with the liposomes for peptide and prevent
its incorporation and disruption of the liposome membranes, in agree-
ment with the present ﬁnding of substantially reduced liposome leak-
age induction by GKS26 in the presence of LPS. While there may
certainly be a barrier function of LPS contributing to this effect as well
[20], results on antimicrobial effects for Gram-negative bacteria show
that this barrier function is not sufﬁcient for preventing the fraction of
peptides not bound to LPS to incorporate into the bacteria membrane
and disrupt these. Also in linewith ﬁndings of the present investigation,
conformational transitions in peptide/LPS complexes have previously
been correlated to anti-inﬂammatory effects, e.g., for fowlicidin-1 frag-
ments [36]. In this context, it is worth noting that peptide-induced LPS
packing transitions may also contribute to peptide anti-endotoxic
effects. For example, both are likely to facilitate phagocytosis, in analogy
to size and charge dependence of phagocytosis of other types of
nanoparticular systems [37]. Through this, an alternative pathway
to inﬂammation-triggering LPS-LBP/CD14 binding/activation is provid-
ed. Indeed, such phagocytosis-based anti-inﬂammatory scavenging
has been previously observed for inﬂammation caused by amyloid Aβ
[38].
Given LPS-induced exposure of both helices A and D on HCII activa-
tion, it interesting to compare the ﬁndings of the present investigation
of helix A-derived GKS26 with those obtained for the analogous helix
D-derived KYE28 (KYEITTIHNLFRKLTHRLFRRNFGYTLR). As GKS26,
KYE28 was previously found to be antimicrobial against both Gram-
negative and Gram-positive bacteria. Analysis of peptide effects on
liposomes and supported lipid bilayers showed that antibacterial action
by KYE28 is caused by direct membrane rupture, where the peptide
binds at high density to the lipid membrane, inserts into this without
insertion threshold, and destabilizes the membrane [27]. In addition,
like GKS26, KYE28 binds extensively to both LPS and its lipid A moiety,
inducing pronounced helix formation in the peptide/LPS complex.
Liposome leakage experiments in the presence and absence of LPS
furthermore showed KYE28 to bind preferentially to LPS over the lipid
membrane, again in agreement with the present results for GKS26.
Also from a biological effect perspective, GKS26 and KYE28 behave
similarly, as both effectively abrogate adverse LPS effects.
Although the biological signiﬁcance of the latter effects remains to
be clariﬁed, the potent antimicrobial and anti-inﬂammatory effects of
GKS26, as well as limited toxicity and restoring effects on platelets,
coagulation, and overall status, indicate a therapeutic potential of this
peptide, offering likely advantages compared to the HCII holoprotein
related to a lower cost of goods and increased stability. As with most
macromolecular therapeutics, peptides of this size will most likely
have to be administered parenterally.With its positive charge and inter-
mediate hydrophobicity, even such routes may provide challenges in
the formof serumprotein binding and uptake in the reticuloendothelial
system (RES), resulting in shortened bloodstream circulation time and
reduced bioavailability. Various approaches can be employed for
reducing such effects, including conjugation with poly(ethylene glycol)
or incorporation of the peptide in a suitable drug carrier [39,40]. In
addition, for continuous infusion, the most likely administration of
peptides against severe infection and sepsis, such serum protein
scavenging does generally not affect bioavailability detrimentally as
peptide is constantly replenished.5. Conclusions
The peptide GKS26, derived from the A domain of HCII, displays
potent antimicrobial effects, also at physiological salt concentration
and in the presence of plasma and serum, related to peptide binding
and destabilization of bacterial lipid membranes. In addition, GKS26
binds extensively to both LPS and its endotoxic moiety lipid A, and
displays potent anti-inﬂammatory effects. The latter extend also to
in vivo models of mice challenged with ip injection of LPS, where
GKS26 suppresses pro-inﬂammatory cytokines, reduces vascular
leakage and inﬁltration of inﬂammatory cells, and normalizes coagula-
tion times. Given this, GKS26 may have therapeutic potential against
severe infection and sepsis.
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